These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27633058)

  • 41. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Singal R; Ramachandran K; Gordian E; Quintero C; Zhao W; Reis IM
    Clin Genitourin Cancer; 2015 Feb; 13(1):22-31. PubMed ID: 25178642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
    Hu L; Sun Y; Luo J; He X; Ye M; Li G; Zhang Y; Bai J; Zhang D; Chang C
    Oncogene; 2020 Feb; 39(9):1891-1903. PubMed ID: 31748715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
    Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
    Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
    Mayer MJ; Klotz LH; Venkateswaran V
    Anticancer Res; 2017 Dec; 37(12):6601-6607. PubMed ID: 29187435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G
    Lee E; Decker AM; Cackowski FC; Kana LA; Yumoto K; Jung Y; Wang J; Buttitta L; Morgan TM; Taichman RS
    J Cell Biochem; 2016 Dec; 117(12):2815-2824. PubMed ID: 27153245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I; Miyake H; Terakawa T; Fujisawa M
    Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
    Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
    Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Mabuchi M; Ueda M; Yoshida Y; Horiike K; Yamaoka K; Nakao S; Shimizu T; Ueda Y; Tsujikawa K; Tanaka A
    Anticancer Res; 2017 Apr; 37(4):1665-1676. PubMed ID: 28373427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
    Wang Q; He WY; Zeng YZ; Hossain A; Gou X
    Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Kong Q; Chen XS; Tian T; Xia XY; Xu P
    Oncol Rep; 2017 Feb; 37(2):803-812. PubMed ID: 27959429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma.
    Wang W; Zhong W; Yuan J; Yan C; Hu S; Tong Y; Mao Y; Hu T; Zhang B; Song G
    Oncotarget; 2015 Dec; 6(39):42276-89. PubMed ID: 26474277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
    Marampon F; Gravina G; Ju X; Vetuschi A; Sferra R; Casimiro M; Pompili S; Festuccia C; Colapietro A; Gaudio E; Di Cesare E; Tombolini V; Pestell RG
    Oncotarget; 2016 Feb; 7(5):5383-400. PubMed ID: 26689991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
    Gonzalez-Moreno O; Segura V; Serrano D; Nguewa P; de las Rivas J; Calvo A
    Int J Cancer; 2007 Sep; 121(6):1197-204. PubMed ID: 17520673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
    Braadland PR; Grytli HH; Ramberg H; Katz B; Kellman R; Gauthier-Landry L; Fazli L; Krobert KA; Wang W; Levy FO; Bjartell A; Berge V; Rennie PS; Mellgren G; Mælandsmo GM; Svindland A; Barbier O; Taskén KA
    Oncotarget; 2016 Jan; 7(2):1878-94. PubMed ID: 26646591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
    Huang J; Jia J; Tong Q; Liu J; Qiu J; Sun R; Yao L; Yang C
    Tumour Biol; 2015 Mar; 36(3):1589-94. PubMed ID: 25377160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.